STRIDE / Hormone Receptor Positive Breast Cancer · Interventional Study

Telehealth Intervention for Symptom Management and Adherence to Adjuvant Endocrine Therapy

ClinicalTrials.gov · August 12, 2026

Preliminary Why this matters to you Expert discussion

Early or partial results. Treat as a signal, not a conclusion.

AI Summary

This is a clinical trial registry record for a planned behavioral telehealth intervention (STRIDE) designed to improve coping with adjuvant endocrine therapy side effects and medication adherence in patients with hormone receptor-positive breast cancer. No results are reported in this registry entry; the study has not yet begun recruiting. The study design, outcomes, and eventual findings remain unknown.

What was studied

Interventional, Randomized, Parallel, Single masking, Supportive Care purpose. Hormone Receptor Positive Breast Cancer; Female; age from 21 Years. Intervention: STRIDE Intervention. Compared with: Usual Care — Active Comparator. n = 400. 2 sites: United States.

Key findings

Safety

Primary outcome is a self-report measure (MOCS-A); no hard clinical endpoints (e.g. medication adherence rates, persistence, discontinuation) are specified in this record.

Who this may help

The source did not state who this applies to in practice.

Plain-language summary

This is a clinical trial registry record describing a planned interventional study with no results reported; the study is not yet recruiting and outcome data are unavailable.

Study design

As stated by the source record.

MethodsPrimary outcome measure: Coping with AET side effects as measured by the Management of Current Stress - Part A (MOCS-A) questionnaire. (assessed at Up to 12 months post-baseline)

DesignInterventional, Randomized, Parallel, Single masking, Supportive Care purpose

PopulationHormone Receptor Positive Breast Cancer; Female; age from 21 Years

Sample size400

InterventionSTRIDE Intervention

ComparatorUsual Care — Active Comparator

Setting2 sites: United States

Reported figures

Quoted from the source exactly as published.

Planned sample size400

Primary outcome measureManagement of Current Stress - Part A (MOCS-A) questionnaire; coping with AET side effects

Follow-up durationUp to 12 months post-baseline

Caveats

This is a registry record only; no results are reported and recruitment has not yet started (NOT_YET_RECRUITING status).
Study phase, randomization method, blinding, and comparator arm definition are not detailed in the registry entry.
Primary outcome is a self-report measure (MOCS-A); no hard clinical endpoints (e.g. medication adherence rates, persistence, discontinuation) are specified in this record.
Actual enrollment, completion rate, and all outcome data are absent from this registry snapshot.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

moderate

Behavioral intervention with comparator arm; phase and blinding status not specified in registry.

Directness

strong

Directly addresses coping with AET side effects and medication adherence in target population.

Consistency

insufficient

Registry record does not report results; no comparison to existing evidence is possible.

Risk of bias

insufficient

Study design details insufficient to assess risk of bias; randomization and blinding not described.

Sample adequacy

moderate

Planned enrollment 400 participants; adequate if powered for primary outcome, not specified.

What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.

Source abstract

Registry record from ClinicalTrials.gov (NCT07759947). This is a study registration, not published results. Lead sponsor: Massachusetts General Hospital. Recruitment status: NOT_YET_RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 400 participants (ESTIMATED). Conditions: Hormone Receptor Positive Breast Cancer. Interventions: BEHAVIORAL: STRIDE; BEHAVIORAL: Usual Care. Primary outcome measures: Coping with AET side effects as measured by the Management of Current Stress - Part A (MOCS-A) questionnaire. , Up to 12 months post-baseline. Brief summary: The goal of this study is to demonstrate the efficacy of an evidence-based, small-group, telehealth intervention ('STRIDE') for improving patients' ability to cope with side effects from adjuvant endocrine therapy (AET) and adhere to AET medication regimens for patients with hormone-sensitive breast cancer.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

STRIDENCT07759947Hormone Receptor Positive Breast CancerMassachusetts General Hospital